Table 1 Demographic and clinical data of patients included in the study
From: Penicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes
Pat | Group | Sex | Age | Drug | Epi | Reaction | IDR (min) | IRS (d) |
|---|---|---|---|---|---|---|---|---|
1 | A | M | 55 | AX-CLV | 1 | Anaphylaxis | 60 | 180 |
2 | B | M | 44 | AX-CLV | 1 | Anaphylaxis | 20 | 60 |
3 | A | M | 46 | AX | 1 | Anaphylaxis | 30 | 30 |
4 | B | M | 55 | AX | 1 | Urticaria | 30 | 300 |
5 | A | M | 62 | AX-CLV | 1 | Anaphylaxis | 60 | 90 |
6 | B | F | 45 | AX-CLV | 1 | Anaphylaxis | 10 | 30 |
7 | B | M | 24 | AX | 1 | Anaphylaxis | 10 | 30 |
8 | B | F | 45 | AX | 1 | Anaphylaxis | 20 | 90 |
9 | A | M | 47 | AX | 2 | Urticaria Anaphylaxis | 40 10 | 477 365 |
10 | A | F | 46 | AX-CLV | 1 | Anaphylaxis | 30 | 120 |
11 | A | M | 43 | AX-CLV | 1 | Anaphylaxis | 45 | 60 |
12 | B | F | 40 | AX/AX-CLV | 2 | Urticaria Anaphylaxis | 30 5 | 112 109 |
13 | A | F | 16 | AX-CLV | 1 | Urticaria | 60 | 30 |
14 | A | M | 27 | AX-CLV | 1 | Anaphylactic shock | 5 | 21 |
15 | A | M | 66 | AX | 1 | Anaphylaxis | 60 | 365 |
16 | B | M | 44 | AX | 1 | Anaphylaxis | 10 | 365 |
17 | A | F | 50 | AX-CLV | 1 | Anaphylaxis | 15 | 30 |
18 | A | M | 44 | AX-CLV | 1 | Anaphylaxis | 10 | 280 |
19 | A | M | 25 | AX-CLV | 1 | Urticaria | 60 | 120 |
20 | B | F | 33 | AX-CLV | 1 | Anaphylaxis | 15 | 6 |
21 | B | F | 36 | AX-CLV | 1 | Anaphylaxis | 30 | 60 |
22 | A | M | 30 | AX | 1 | Anaphylaxis | 5 | 20 |
23 | B | M | 45 | AX-CLV | 1 | Anaphylactic shock | 5 | 30 |
24 | A | M | 30 | AX-CLV | 1 | Anaphylaxis | 30 | 210 |
25 | B | M | 57 | AX-CLV | 1 | Anaphylaxis | 5 | 60 |
26 | A | M | 49 | AX | 1 | Anaphylaxis | 10 | 120 |
27 | A | F | 39 | AX | 1 | Urticaria | 40 | 40 |
28 | A | F | 39 | AX-CLV | 1 | Urticaria | 60 | 95 |
29 | A | F | 21 | AX-CLV | 1 | Anaphylaxis | 15 | 230 |
30 | A | M | 46 | AX-CLV | 1 | Anaphylaxis | 2 | 137 |
31 | B | M | 49 | AX | 1 | Anaphylaxis | 5 | 180 |
32 | B | F | 37 | AX-CLV | 1 | Anaphylaxis | 20 | 30 |
33 | A | F | 57 | AX | 1 | Anaphylaxis | 30 | 90 |
34 | B | M | 26 | AX | 1 | Anaphylaxis | 20 | 10 |
35 | B | M | 48 | AX-CLV | 1 | Anaphylaxis | 60 | 146 |
36 | A | M | 23 | AX-CLV | 1 | Anaphylaxis | 50 | 60 |
37 | B | F | 42 | AX | 1 | Anaphylaxis | 5 | 120 |
38 | B | M | 57 | AX-CLV | 1 | Anaphylaxis | 30 | 28 |
39 | B | M | 30 | AX-CLV | 1 | Urticaria | 10 | 730 |
40 | A | F | 37 | AX-CLV | 1 | Anaphylaxis | 5 | 30 |
41 | A | F | 14 | AX-CLV | 1 | Anaphylaxis | 10 | 90 |
42 | A | M | 44 | AX | 1 | Urticaria | 30 | 120 |
43 | A | M | 28 | AX | 2 | Anaphylaxis Anaphylaxis | 20 25 | 230 180 |
44 | A | M | 63 | AX-CLV | 1 | Anaphylaxis | 10 | 30 |
45 | A | M | 51 | AX | 1 | Urticaria | 60 | 30 |
46 | A | M | 35 | AX | 1 | Urticaria | 30 | 90 |
47 | A | M | 32 | AX | 1 | Anaphylaxis | 45 | 180 |
48 | A | M | 53 | AX | 1 | Anaphylaxis | 30 | 90 |
49 | A | M | 44 | AX | 1 | Urticaria | 45 | 120 |
50 | A | F | 38 | AX-CLV | 1 | Anaphylaxis | 10 | 30 |
51 | A | M | 54 | AX-CLV | 1 | Anaphylactic shock | 5 | 90 |
52 | A | F | 62 | AX-CLV | 1 | Urticaria | 60 | 210 |
53 | B | M | 49 | AX-CLV | 1 | Anaphylaxis | 30 | 120 |
54 | A | F | 44 | AX | 1 | Anaphylactic shock | 5 | 240 |